Loading company details...
Latest Form 4 (Oct 9, 2026): Adam Schayowitz (EVP, Head of R&D): Exercise/Conversion of 37,037 shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 9, 2026 | Adam Schayowitz, EVP, Head of R&D | Exercise/Conversion | 37,037 | n/a |
| Jul 6, 2026 | Mark Hollywood, EVP & Chief Operating Officer | Grant/Award | 939 | $20.9K |
| May 15, 2026 | Paul R. Schneider, EVP, General Counsel | Grant/Award | 178,000 | n/a |
| Apr 10, 2026 | Adam Schayowitz, EVP, Head of Research & Development | Grant/Award | 70,000 | n/a |
| Apr 10, 2026 | Scott Platshon, EVP, Chief Business Officer | Grant/Award | 70,000 | n/a |
| Apr 7, 2026 | Kristin Stafford, EVP, Chief Financial Officer | Grant/Award | 178,000 | n/a |
| Jan 13, 2026 | Mark Hollywood, EVP & Chief Operating Officer | Exercise/Conversion | 17,666 | n/a |
| Jan 13, 2026 | Brian N. Cherry | Grant/Award | 23,000 | n/a |
| Jan 13, 2026 | Jeffrey T. L. Smith, EVP & Chief Medical Officer | Exercise/Conversion | 17,666 | n/a |
| Jan 13, 2026 | Gregory Austin Ciongoli | Grant/Award | 11,500 | n/a |